Aoxing Pharma Advances Two Opioid Products in China

Aoxing Pharma, a US-headquartered company whose operations are in China, reported positive results from a China registrational trial of buprenorphine/naloxone sublingual tablets as a treatment for opioid dependence. Aoxing has a license to produce narcotic drugs in China, and buprenorphine is an opioid derivative. Last week, Aoxing received marketing approval for its Tilidine Hydrochloride pain medication, a synthetic opioid that is used to treat pain in several countries around the world. More details.... Stock Symbol: (NYSE: AXN) Share this with colleagues: // //